Plasma cell leukemia

From WikiMD.org
Jump to navigation Jump to search

Plasma Cell Leukemia (pronunciation: plaz-muh sel loo-kee-mee-uh) is a rare and aggressive subtype of Multiple Myeloma, a type of cancer that starts in the plasma cells in the bone marrow.

Etymology

The term "Plasma Cell Leukemia" is derived from the Greek words "plasma" (meaning "moldable substance"), "kytos" (meaning "cell"), "leukos" (meaning "white"), and "haima" (meaning "blood").

Definition

Plasma Cell Leukemia is characterized by a high number of malignant plasma cells circulating in the peripheral blood. It is classified into two types: Primary Plasma Cell Leukemia, which occurs de novo, and Secondary Plasma Cell Leukemia, which evolves from pre-existing Multiple Myeloma.

Symptoms

Symptoms of Plasma Cell Leukemia may include fatigue, bone pain, and frequent infections. It may also cause anemia, kidney damage, and high levels of calcium in the blood.

Diagnosis

Diagnosis of Plasma Cell Leukemia involves blood tests, bone marrow biopsy, and imaging tests. The presence of more than 20% of plasma cells in the peripheral blood or an absolute plasma cell count of more than 2 x 10^9/L is indicative of Plasma Cell Leukemia.

Treatment

Treatment options for Plasma Cell Leukemia may include chemotherapy, stem cell transplant, and targeted therapy. The choice of treatment depends on the patient's overall health, the extent of the disease, and the patient's personal preferences.

Prognosis

The prognosis of Plasma Cell Leukemia is generally poor, with a median survival of less than a year. However, survival rates may improve with newer treatment options.

See Also

External links

Esculaap.svg

This WikiMD article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski